Ketoconazole Trial for Mild Autonomous Cortisol Secretion Shows Potential to Lower Cortisol Levels
A clinical trial is underway to evaluate the effects of ketoconazole on cortisol levels in patients with mild autonomous cortisol secretion (MACS).
Asset / Drug
Drug and asset intelligence for ketoconazole with 1 indexed intelligence signal across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
No catalysts indexed for this entity yet.
No related entities indexed yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.